LTRN
Lantern Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Stock Price Surged Significantly
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LTRN
Lantern Pharma Inc.
A clinical stage biopharmaceutical company that develops oncology-based therapeutics for the treatment of cancer
Biological Technology
11/07/2013
06/11/2020
NASDAQ Stock Exchange
24
12-31
Common stock
1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201
--
Lantern Pharma Inc., was founded on November 7, 2013. The company is a clinical-stage biotechnology company that leverages artificial intelligence (" A.I. "), machine learning and genomic data to simplify drug development processes and enable patients to be treated to benefit from its targeted tumor therapies.
Earnings Call
Q1/2025
Estimate EPS-0.49
Actual EPS-0.42
Estimate Revenue--
Actual Revenue0
Lantern Pharma's Q1 2025: Navigating Contradictions in AI Strategy, FDA Adoption, and HARMONIC Trial Design
May 21,2025 12:41
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.47
Actual EPS-0.39
Estimate Revenue--
Actual Revenue0
Q3 2025 Earnings Call Contradictions: AI Monetization, withZeta, and Trial Timelines
Nov 13,2025 01:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LTRN has released its 2025 Q3 earnings. EPS was reported at -0.39, versus the expected -0.47, beating expectations. The chart below visualizes how LTRN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
